SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs has drawn attention, with traders citing BRIUMVIs sales growth and the Q3 results and subcutaneous Phase 3 data as key business catalysts. Buyout speculationparticularly involving Sanofiand hopes for short covering are widespread, but no deal is confirmed; some investors argue that execution matters more than takeover chatter.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is discussing access to a large number of U.S. cell sites have focused attention on Crown Castle as traders weigh potential new tower-leasing demand for Starlink Mobile. Bulls see a hybrid satellite-and-terrestrial network as a boost for tower owners, while skeptics note that no agreement is signed and question execution, regulatory approval, and whether speculation has already driven the move.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,967,326.643147 in circulation. The last known price of Algorand is 0.09515711 USD and is down -0.23 over the last 24 hours. It is currently trading on 586 active market(s) with $49,581,617.87 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention around a contested recovery thesis: bullish traders cite technical support, rebounds and a possible altcoin rotation, while bears point to persistent underperformance and the risk of further declines. Some bulls also highlight Algorands quantum-resistant technology and tokenization or payment use cases, though these are longer-term narratives rather than a confirmed near-term catalyst.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

A volatile LINK rebound and repeated resistance tests are driving discussion, with bulls pointing to Chainlinks institutional and tokenization integrations, including its role in Coinbases Base tokenized-stock offering and CCIP 2.0. Skeptics warn that rallies have faded before and question whether network adoption will translate into value for the LINK token.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

BTDR is under pressure alongside Bitcoin miners and AI infrastructure stocks as traders cite Bitcoin weakness and a recent downgrade; some also blame short-selling, though that remains speculation. The community is split between calling the selloff an opportunity ahead of earnings and worrying the decline could continue, with many frustrated by BTDRs lagging performance versus peers.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas upcoming addition to the S&P 500 is a major topic, with traders weighing expected index-fund buying against a possible sell-the-news move as the shares weaken. Some posts also cite an alleged DHS-related breach, but those claims are unverified in the discussion.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans strong third-quarter results, higher full-year outlook and record backlog are driving discussion, with traders pointing to sustained defense demand. The reaction is mixed: some see the fundamentals as support for the shares, while others question the rally and expect a pullback.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is drawing attention after dazodalibep met its Phase 3 endpoint in Sjgrens disease, with traders viewing the result as a pipeline catalyst. The discussion also cites strong IMDELLTRA/Imfinzi small-cell lung cancer data, alongside questions about whether recent momentum is already priced in.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

A newly disclosed performance-based option award for CEO Gregory Demopulos is drawing attention, with traders debating whether its stock-price and service conditions align his incentives with shareholders. The broader discussion remains focused on YARTEMLEAs U.S. sales growth and the next quarterly results, with bullish expectations balanced by caution after the European regulatory rejection.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Q4 topline results from its Phase 3 HLP003 trial for major depressive disorder, a pivotal catalyst for the clinical-stage biotech. Traders are optimistic about the treatments potential as an add-on to existing antidepressants, but debate the binary trial risk, possible dilution and how results could compare with peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Russell 1000 ETF (IWB) Be on Your Investing Radar?

Russell, MSCI And Morningstar Set To Load Up On SpaceX Stock — Analyst Warns ‘True Value’ May Be Hard To Pin 

Equity

Index funds will be forced to buy more SpaceX shares as insiders sell, Morningstar said.

Noteworthy ETF Outflows: IWB, PG, HD, KO

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $296.3 million dollar outflow -- that's a 0.6% decrease week over week...

IWB, WMT, ABBV, MA: ETF Outflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $613.1 million dollar outflow -- that's a 1.3% decrease week over week...

Noteworthy ETF Inflows: IWB, LLY, XOM, V

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $381.4 million dollar inflow -- that's a 0.8% increase week over week in...

IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying 

IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.

Notable ETF Outflow Detected - IWB, LLY, V, CAT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $683.7 million dollar outflow -- that's a 1.5% decrease week over week...

Bullish Two Hundred Day Moving Average Cross - IWB

In trading on Wednesday, shares of the iShares Russell 1000 ETF (Symbol: IWB) crossed above their 200 day moving average of $363.78, changing hands as high as $371.46 per share. iShares Russell 1000 shares are currently trading up about 2.2% on the day. The chart below shows t...

iShares Trust - iShares Russell 1000 ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Morningstar said SpaceX’s weighting in the Russell 1000, Morningstar US Total Market and MSCI USA indexes is set to at least double at upcoming rebalances.</li><li>More than 900 million additional SpaceX shares became eligible for insider sales on Aug.6.</li><li>Morningstar estimates the larger float could propel SpaceX into the Russell 1000’s top 100 holdings.</li></ul>Shares of SpaceX (SPCX) rose 1% overnight late Wednesday as Morningstar said major indexes are preparing to increase the stock’s weighting, forcing index funds to buy more shares just as insiders gain the ability to sell more than 900 million shares.<a href="https://stocktwits.com/symbol/SPCX">SPCX stock</a> gained 1.2% on Wednesday to close at $139.63 and added another 0.6% after-hours.<h2 class="st-heading-2">SpaceX Index Weight Set To Double</h2>“Something odd is going on,” Morningstar said, noting that SpaceX’s weight in the Russell 1000, Morningstar US Total Market and MSCI USA indexes is set to at least double “no matter if its stock price rises or falls” before upcoming rebalances.These indexes use free-float-adjusted market cap, counting only publicly tradable shares. SpaceX’s limited float explains why its $1.4 trillion valuation at the end of July earned it the same 0.08% Russell 1000 weight as $57 billion Delta Air Lines.More than 900 million additional SpaceX shares became eligible for sale by insiders on Aug. 6, which is equal to 143% of the 639 million shares available for public trading shortly after the company’s IPO. Morningstar estimated that the release could increase SpaceX’s float-adjusted market value by 2.43 times, lifting its Russell 1000 weight to about 0.2% and placing it among the index’s top 100 holdings. Assuming July 31 prices, its weight could hit 0.7% following the Dec.11 rebalance.<h2 class="st-heading-2">Index Funds Forced To Buy SpaceX&nbsp;</h2>“Index funds will be forced to buy more SpaceX stock just as insiders are selling,” Morningstar said, warning that “it may be hard to determine the stock’s true value and trading equilibrium in the short term.”The dynamic is unusual as SpaceX shares fell 31% in July. While falling market values typically reduce index weights, the expansion of SpaceX’s tradable float is expected to outweigh its stock decline. “This flies in the face of market-cap weighting,” the brokerage said.Funds including the iShares Russell 1000 ETF (IWB), Vanguard Total Stock Market ETF (VTI) and Invesco MSCI USA ETF (PBUS) bought SpaceX shortly after its June high and held it through its July lows. The Nasdaq 100, tracked by the Invesco QQQ Trust (QQQ), added SpaceX on July 7. The S&amp;P 500 cannot add SpaceX before June 2027 because of its one-year seasoning requirement, while profitability rules could delay inclusion further. Morningstar expects SpaceX to remain below 1% of major U.S. indexes in the near term.<h2 class="st-heading-2">Wolfe Sees 25% SpaceX Upside</h2>Separately, Wolfe Research called SpaceX’s upcoming Louisiana spaceport and recent White House launch-regulation relief “bullish indicators for one of the biggest external constraints on SpaceX’s ambitions.” The brokerage said that the project “paves the way to alleviate the most obvious external constraint” to Starship’s rapid-reuse ambitions.Wolfe maintained an ‘Outperform’ rating and $175 price target, implying a 25% upside from current levels. The firm identified a successful orbital Starship Flight 14 in early September as the next potential catalyst. SpaceX plans to invest $100 billion in the Louisiana facility, which is expected to become Starship’s primary launch hub and support thousands of launches annually. Musk said it could create “probably 10,000 really exciting jobs.” The facility is key to SpaceX’s plans to expand Starlink, deploy orbital data centers and eventually reach Mars.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SPCX?</h2>On Stocktwits, retail sentiment for SPCX declined to ‘bearish’ from ‘neutral’ levels a week ago amid a 6% rise in 24-hour message volumes.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/spcx_ss_9cb52fb5e5.png" alt="spcx ss.png" width="644" height="341"><figcaption>SPCX sentiment and message volume as of August 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Chark/message/662923012">said</a>, “$SPCX Breakout!!!! Stay with me Bulls! This is just getting warmed up!&nbsp; Going to need more jet fuel!!!!”<stembedurl>https://stocktwits.com/Chark/message/662923012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Danz_Trades/message/662956136">said</a>, “$SPCX is getting ready to retest $145-$150 if buyers can hold above $140. Above $150 IPO high then we shall see $160 quickly”<stembedurl>https://stocktwits.com/Danz_Trades/message/662956136</stembedurl>SPCX stock has fallen 13% over the past three months.&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rocketlab-insiders-sell-shares-iridium-deal-ceo-secret-defense-programs/cZY8oDBRJpj">Rocket Lab Insiders Sell $5.5M Worth Of Shares As Iridium Deal Advances — CEO Teases Secret Defense Programs&nbsp;</a>

The logo of SpaceX is displayed on a smartphone screen. (Photo by VCG/VCG via Getty Images)

Russell, MSCI And Morningstar Set To Load Up On SpaceX Stock — Analyst Warns ‘True Value’ May Be Hard To Pin

Delta Air Lines, Inc.

iShares Russell 1000 ETF

Invesco MSCI USA ETF

SpaceX

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IWB iShares Russell 1000 ETF

Fundamentals

Latest IWB News